Pharma BD Deal Intelligence
Glaxo investing about $1 billion to raise its stake in its Indian drug unit to 75%, offering Rs 3,100 a share, a 26% premium over the prior close.
GlaxoSmithKline takes firmer control over its Indian operation, with the deal underscoring the British drugmaker's drive to deepen its presence in emerging…
GSK confirmed open offer success, lifting stake to 75% — the maximum allowed under Indian listing rules — for total consideration of approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK launched voluntary open offer at INR 3,100/share (26% premium) to raise stake in GSK Pharmaceuticals India from 50.7% to 75% — total cost ~£629M (~$1.02B).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / GlaxoSmithKline Pharmaceuticals Limited (India) — minority stake increase (this deal) | 2013 | $1.0B | 43 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2013 deals · GlaxoSmithKline plc deals · Other deals